InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
0
T+90 hit rate
29%
T+90 mean return
-4.5%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by BRADY ANN, Chairman & CEO. Officer active across 1 company, notably Theravance Biopharma, Inc.. Cumulatively, 7 filings have been published. History available since 20 May 2021. The latest transaction was disclosed on 18 February 2022 (Retenue fiscale). Regulator: SEC (Form 4). All data is free.
Declarations7 total
8,369 shares@ US$9.610.0085% mcap24.7% of flowOrdinary SharesSEC:0001415889-22-001693:0
3,169 shares@ US$8.368.2% of flowOrdinary SharesSEC:0001415889-21-005472
3,169 shares@ US$8.360.0028% mcap8.2% of flowOrdinary SharesSEC:0001415889-21-005472:0
3,169 shares@ US$14.050.0046% mcap13.3% of flowOrdinary SharesSEC:0001179110-21-008390:0
3,169 shares@ US$14.0513.3% of flowOrdinary SharesSEC:0001179110-21-008390
3,169 shares@ US$17.8016.1% of flowOrdinary SharesSEC:0001179110-21-005838
3,169 shares@ US$17.800.0055% mcap16.1% of flowOrdinary SharesSEC:0001179110-21-005838:0
7 of 7 declarations
About BRADY ANN
Ann Brady is the Chairman & CEO of Theravance Biopharma, Inc. She leads the company's operations and is responsible for the overall strategy. Her role includes overseeing research and development activities and managing stakeholder relationships. She plays a key role in the growth and innovation of the organization.
